SEARCH

SEARCH BY CITATION

References

  • 1
    McNeal JG The prostate gland: morphology and pathobiology. Monogr Urol 1983; 4: 3 33
  • 2
    Berry SJ, Coffey DS, Walsh PC et al. The development of human prostatic hyperplasia with age. J Urol 1984; 132: 474 9
  • 3
    Oesterling JE, Jacobsen SJ, Chute CG et al. Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges. JAMA 1993; 270: 860–4
  • 4
    Baily MJ & O’Leary MP The development and clinical utility of symptom scores. Urol Clin N 1995; 22: 229 307
  • 5
    Girman CJ, Jacobsen SJ, Guess HA et al. Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol 1995; 153: 1510 5
  • 6
    Shapiro E & Lepor H Pathophysiology of clinical BPH. Urol Clin N 1995; 22: 285 90
  • 7
    Isaacs JT & Coffey DS Etiology and disease process of benign prostatic hyperplasia. Prostate 1989; 2: 33 50
  • 8
    Gup DI, Shapiro E, Baumann M, Lepor H Autonomic receptors in asymptomatic and symptomatic BPH. J Urol 1990; 143: 179 85
  • 9
    Caine M The present role of alpha adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol 1986; 136: 1 6
  • 10
    Lepor H and the Multicenter Study Group Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urol 1995; 45: 406 13
  • 11
    Lepor H Natural history, assessment of efficacy and nonsurgical treatment of BPH. In Walsh PC et al.., eds Campbell’s Urology, Vol. 17. Philadelphia: W.B. Saunders Co,1998; in press
  • 12
    Barry MJ, Cockett ATK, Holtgrewe HL et al. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 1993; 150: 351 8
  • 13
    Nitti V, Kim Y, Combs AJ Correlation of the AUA symptom index with urodynamics in patients with suspected benign prostatic hyperplasia. Neurourol Urodyn 1994; 13: 521 9
  • 14
    Tsukamoto T, Kumamoto Y, Masumori N et al. Prevalence of prostatism in Japanese men in a population-based study with comparison to a similar American study. J Urol 1995; 154: 391 5
  • 15
    Lepor H & Machi GM Comparison of the AUA symptom index in unselected males and females between 55 and 79 years of age. Urol 1993; 42: 36
  • 16
    Caine M, Pfau A, Perlberg S The use of alpha adrenergic blockers in benign prostatic obstruction. Br J Urol 1976; 48: 255
  • 17
    Shapiro E, Hartanto V, Lepor H Anti-desmin vs. anti-actin for quantifying the area density of prostate smooth muscle. Prostate 1992; 20: 259 67
  • 18
    Gup DI, Shapiro E, Baumann M et al. The contractile properties of human prostate adenomas and the development of infravesical obstruction. Prostate 1989; 15: 105 14
  • 19
    Shapiro E, Becich MJ, Lepor H The relative proportion of stromal and epithelial hyperplasia as related to the development of clinical BPH. J Urol 1992; 147: 1293 7
  • 20
    Lepor H, Shapiro E, Browsher R, Henry D Tissue norepinephrine levels in prostate adenomas from men with symptomatic and asymptomatic BPH. J Urol 1990; 144: 1263 6
  • 21
    Shapiro E, Hartanto V, Lepor H The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 1992; 21: 297 307
  • 22
    Lepor H & Rigaud G The efficacy of transurethral resection of the prostate in men with moderate symptoms of prostatism. J Urol 1990; 143: 533 7
  • 23
    Lepor H, Williford WO, Barry MJ et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. New Eng J Med 1996; 335: 533 9
  • 24
    Lepor H, Nieder A, Dixon CM et al. The effectiveness of terazosin in men with normal and abnormal peak flow rates. Urology 1998; in press.